July 10, 2020 05:26 PM RSS

WHO Halts Hydroxychloroquine Study on Safety Concerns

  • Wall Street Rebel | James DiGeorgia
  • 05/25/2020 5:13 PM
WHO Halts Hydroxychloroquine Study on Safety Concerns

The World Health Organization (WHO) has temporarily halted tests on hydroxychloroquine in its COVID-19 drug trials, pending more data over concerns of safety


May 25, 2020

COVID-19 Coronavirus Outbreak – World StatisticsEmail

Coronavirus Cases:

5,567,673

Closed Cases:

2,700,100

Deaths:

346,892

Recovered:

2,353,2-8

Currently Infected Patients

2,867,573

 

 

United States COVID-19 Coronavirus  May 25, 2020

www.worldometers.info/coronavirus

 

Total Coronavirus Cases:

1,702,685

Active Cases:

1,142,086

Closed Cases:

560,599

Deaths:

99,743

Recovered:

460,856


 

 

President Trump has received potentially devastating news in his attempt to gaslight Americans on his miracle cure hydroxychloroquine.  Trump managed to get the Federal Government and State Governments to spend tens of millions of dollars on in the last couple of months, despite repeated studies that seem to conclude the same thing. Hydroxychloroquine is potentially lethal to those sick with COVID-19.

The World Health Organization (WHO) steering committee decided to suspend enrollment to the so-called hydroxychloroquine solidarity trials.  Only days after the internationally prestigious medical research magazine Lancet published a study that said the drug, that has been touted by U.S. President Donald Trump, and Brazil’s President Jair Bolsonaro as a treatment and preventative prophylactic for COVID-19, the suspended trials. Hydroxychloroquine has been linked to an increased risk of death and heart ailments.

WHO Chief Scientist Soumya Swaminathan said at a press briefing in Geneva…

“It’s important to continue to gather evidence on the efficacy and safety of hydroxychloroquine…We want to use it if it’s safe and efficacious, reduces mortality, reduces the length of hospitalization without increasing adverse events.”

Mike Ryan, head of the WHO’s Health Emergencies Program, said at a briefing….

“The studies may resume if data warrants, and there were no signals from the Solidarity trials that indicate any problem. The decision was made out of an “abundance of caution” for the patients participating in the WHO study.”

Swaminathan also pointed out that…

“The safety monitoring board will meet again, and the decision will be reviewed in the next week or two.”


    WHO suspends clinical trial of hydroxychloroquine for COVID-19


 

[Strategic Investment: The Post WWII World Order is About to Collapse]

Become A Wall Street Rebel

[Image: Pile of cash]
Rebel Yell Morning Market Report
Market Alerts
New product announcements, money-saving deals, and special discounts from our investment newsletters.
News and valuable offers about my health, investing, and special interests from our trusted partners.

Latest News